Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...

However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

The Hancock County Commission will be receiving additional funds as part of an antitrust lawsuit filed by the State of West ...

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...